May 12, 2025
Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders
Sirius Therapeutics has secured around $50m in a Series B2 funding round for the clinical development of small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders.